Lentiviral vectors are attractive candidates for gene therapy because of their ability to
integrate into nondividing cells. To date, conventional HIV-1-based vectors can be produced …

In contrast to oncoviruses, lentiviruses do not require target cell division for integration into
the host genome. Lentiviral vectors can therefore expand the spectrum of target cells …

Lentivirus vectors based on human immunodeficiency virus (HIV) type 1 (HIV-1) constitute a
recent development in the field of gene therapy. A key property of HIV-1-derived vectors is …

The improvement of gene transfer efficiency in growth-arrested cells using human
immunodeficiency virus type 1 (HIV-1)-derived vectors led to the development of vectors …

The development of highly efficient and safe gene transfer methods suitable for clinical use
is required for human gene therapies. We have developed a novel lentiviral vector system …

Background Lentiviral vectors allow gene transfer into non‐dividing cells. Further
development of these vector systems requires stable packaging cell lines that enable …

The use of human immunodeficiency virus vectors for gene therapy is hampered by concern
over their safety. This concern might be ameliorated, in part, if the viral accessory genes and …

Lentivirus-derived vectors are very promising gene delivery systems since they are able to
transduce nonproliferating differentiated cells, while murine leukemia virus-based vectors …

Heterologous lentiviral vectors (LVs) represent a way to address safety concerns in the field
of gene therapy by decreasing the possibility of genetic recombination between vector and …

Lentiviral vectors based on human immunodeficiency virus type 1 (HIV-1) possess the ability
to deliver exogenous genes to both dividing and nondividing cells and to subsequently …